you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes

October 2012

New concerns about bladder cancer mean you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes.

Pioglitazone is off the market in France while authorities investigate. Regulators in other countries are also assessing its risks.

Advise keeping the potential risk in perspective.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Vaccines More pharmacists will be giving flu vaccines this year
Infectious Diseases new LESS concentrated Tamiflu (oseltamivir) suspension this flu season
Infectious Diseases more attention on West Nile virus in the future
Osteoarthritis Cymbalta (duloxetine) for chronic pain due to osteoarthritis of the knee
Hypertension debate about when to start drugs in patients with MILD hypertension
Antipsychotics whether it makes sense to use more than one antipsychotic for schizophrenia
Migraine new option to treat acute migraine attacks called Cambia (KAM-bee-ah)
Depression more emphasis on treating depression in cardiac patients
Respiratory & Allergy whether inhaled corticosteroids inhibit growth in kids or increase fracture risk in seniors
Statins whether statins increase the risk of cataracts
Substance Use Disorder People are abusing Suboxone (buprenorphine/naloxone) tabs
Diabetes you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes